BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22196919)

  • 1. Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy.
    Koh PK; Faivre-Finn C; Blackhall FH; De Ruysscher D
    Cancer Treat Rev; 2012 Oct; 38(6):626-40. PubMed ID: 22196919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
    Xu Y; Zhang Y; Ma S
    Lung Cancer; 2011 Sep; 73(3):249-55. PubMed ID: 21641672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
    Kim DW; Choy H
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):11-20. PubMed ID: 15142630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P; Gridelli C; Troiani T; Ciardiello F
    Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directed therapies in lung cancer: new hope?
    Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
    Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate?
    Martinez P; Martinez-Marti A; Navarro A; Cedrés S; Felip E
    Lung Cancer; 2014 May; 84(2):97-100. PubMed ID: 24582269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC.
    Rogers SJ; Harrington KJ; Eccles SA; Nutting CM
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):569-83. PubMed ID: 15270661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized medicine for non-small-cell lung cancer.
    Mok TS; Zhou Q; Leung L; Loong HH
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
    Batus M; Fidler MJ; Bonomi PD
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-directed therapies to treat non-small-cell lung cancer.
    Ho C; Laskin J
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies and non-small-cell lung cancer: new developments.
    Gridelli C
    Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors.
    Kotteas EA; Charpidou AG; Syrigos KN
    Anticancer Drugs; 2010 Feb; 21(2):151-68. PubMed ID: 20016368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Targeted therapies and radiation therapy in non-small cell lung cancer].
    Rivera S; Quéro L; Wong Hee Kam S; Maylin C; Deutsch E; Hennequin C
    Cancer Radiother; 2011 Oct; 15(6-7):527-35. PubMed ID: 21885318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 20. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
    Reungwetwattana T; Weroha SJ; Molina JR
    Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.